Theriva Biologics (TOVX) Q1 2026 Earnings
TOVX·Reported May 7, 2026·Before market open
Theriva Biologics reported Q1 2026 revenue of $300.0K. Diluted EPS came in at $-0.05 (+96.8% YoY).
Revenue
$300.0Kmet estimate
Consensus: $300.0KDiluted EPS
$-0.05met estimate
Consensus: $-0.05
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Theriva Biologics's Q1 2026 earnings report.
Theriva Biologics (TOVX) reported Q1 2026 earnings on May 7, 2026 before market open.
Theriva Biologics reported revenue of $300.0K and diluted EPS of $-0.05 for Q1 2026.
Revenue beat the consensus estimate of $300.0K by -. EPS beat the consensus estimate of $-0.05 by $0.00.
Compared to the same quarter a year prior, diluted EPS grew 96.8% from $-1.55.
You can read the 8-K earnings release (0001104659-26-055679) and the 10-Q periodic report (0001104659-26-055689) directly on SEC EDGAR. The filing index links above go to sec.gov.